Analysts Set OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Target Price at $6.33

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have received a consensus recommendation of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $6.3333.

A number of equities analysts have recently commented on OKYO shares. B. Riley Financial started coverage on shares of OKYO Pharma in a research note on Monday, December 8th. They issued a “buy” rating and a $5.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of OKYO Pharma in a report on Thursday, January 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a research report on Thursday, January 22nd. Finally, Piper Sandler started coverage on OKYO Pharma in a research note on Friday, February 20th. They set an “overweight” rating and a $7.00 price objective on the stock.

OKYO Pharma Price Performance

OKYO opened at $1.62 on Tuesday. OKYO Pharma has a 1 year low of $1.03 and a 1 year high of $3.35. The firm has a 50 day moving average price of $1.97 and a 200 day moving average price of $2.10.

OKYO Pharma (NASDAQ:OKYO) last announced its quarterly earnings results on Friday, January 30th. The company reported ($2.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($2.21). As a group, analysts forecast that OKYO Pharma will post -0.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OKYO Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC purchased a new position in OKYO Pharma in the 3rd quarter worth approximately $31,000. XTX Topco Ltd purchased a new stake in shares of OKYO Pharma during the fourth quarter valued at approximately $36,000. Finally, Renaissance Technologies LLC raised its stake in shares of OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after purchasing an additional 96,800 shares during the period. 2.97% of the stock is owned by institutional investors and hedge funds.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.